CD4 and infection: Two studies conducted in Western Kenya [22] and in rural Zimbabwe [23] found no significant difference in praziquantel efficacy in S. mansoni HIV-1 seronegative or seropositive individuals, in terms of cure rates or in reduction in intensity of infection, nor was there any influence of the CD4+ level on the treatment outcome [22, 23].